Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 34 projects, of which 14 are in clinical development.
| Karolinska Development presents at "Avanza Banks Börsdag", November 29, 2011 Click to listen to the webcast (only in Swedish) |
 |
Axelar reports good safety profile of AXL1717 in Phase I/II in cancer patients |
VIEW PORTFOLIO BY THERAPEUTIC AREA:
Click to view portfolio progress
KDEV
Press Releases
-
2012-01-16
Pergamum initiates Phase II trial with DPK-060 in outer ear infections
-
2012-01-09
Akinion Pharmaceuticals initiates Phase I/II clinical trial with AKN-028
-
2011-12-28
Axelar initiates a Phase II clinical study with AXL1717 for the treatment of non-small cell lung cancer
Financial Reports
Interim report January - September 2011
News
2012-01-25 ProNoxis AB
ProNoxis AB has secured SEK 4.0 million in a new round of financing
2012-01-09 Akinion Pharmaceuticals AB
Akinion Pharmaceuticals appoints Carl Harald Janson as CEO
2011-12-22 Aprea AB
Aprea strengthens its board